Results 151 to 160 of about 49,569 (265)

Role of Mast Cells and Neuroinflammation in Neuropsychiatric Disorders of the Developmental Period. [PDF]

Biomolecules
Aitella E, Neri L, Azzellino G, Romano C, De Martinis M, Roncone R, Ginaldi L.   +6 more
europepmc   +1 more source

CD93—An emerging vascular target in cancer therapy

British Journal of Pharmacology, EarlyView.
Abstract CD93 is a single‐pass transmembrane glycoprotein that belongs to the C‐type lectin domain group XIV family of proteins. Although it is known to be expressed in other cell types, namely, in some subsets of immune cells, CD93 is primarily expressed on endothelial cells, where it acts as a crucial regulator of angiogenesis.
Beatriz de Alves Pereira, Stefano Barbera, Roberta Lugano, Anna Dimberg   +3 more
wiley   +1 more source

Mirtazapine is a functional antagonist at cardiac human H₁-histamine receptors. [PDF]

Naunyn Schmiedebergs Arch Pharmacol
Pham TH, Schlicht JMA, Hofmann B, Kirchhefer U, Neumann J, Gergs U.   +5 more
europepmc   +1 more source

Muscarinic agonists for schizophrenia: Bridging preclinical evidence and clinical enthusiasm

British Journal of Pharmacology, EarlyView.
Abstract Antipsychotic drugs targeting dopamine receptors have been used to treat schizophrenia for decades, primarily alleviating positive symptoms such as hallucinations and delusions. However, they provide limited benefit for cognitive and negative symptoms—major contributors to poor outcomes—and are frequently associated with significant side ...
Brian J. Morris, Judith A. Pratt
wiley   +1 more source

Chronic spontaneous cholinergic urticaria: advances in immunological mechanisms focusing on neuro-immune crosstalk and novel targeted therapeutic strategies. [PDF]

Front Immunol
Yang M, Lin S, Lu Y, Jin H, Zhang X, Chen Z.   +5 more
europepmc   +1 more source

Remibrutinib (Rhapsido) for chronic spontaneous urticaria. [PDF]

Trends Pharmacol Sci
Lamkin EN, Bravo E, Taylor J.
europepmc   +1 more source

β-Hydroxybutyrate attenuates bronchial smooth muscle proinflammatory cytokine production and contraction. [PDF]

Am J Physiol Cell Physiol
Fastiggi VA, Mank MM, Caporizzo MA, Poynter ME.   +3 more
europepmc   +1 more source

Rebound Pruritus and Urticaria After Discontinuation of Chronic Antihistamine Use—A Scoping Review

Clinical &Experimental Allergy, EarlyView.
Rebound pruritus and urticaria have been reported after discontinuation of chronic cetirizine or levocetirizine use only. Symptoms typically occur within 0.5–5 days after stopping therapy and appear more frequently reported in female patients. Re‐initiation of antihistamines is the most commonly effective management strategy, highlighting the need for ...
Jun Jie Benjamin Seng, Prawira Oka, Ngiap Chuan Tan   +2 more
wiley   +1 more source

Targeting immune dysregulation in chronic spontaneous urticaria: beyond antihistamines. [PDF]

Korean J Intern Med
Ye YM.
europepmc   +1 more source

Neurotransmitter Dysregulation in Parkinson's Disease: Pathophysiological Insights and Therapeutic Perspectives. [PDF]

ACS Chem Neurosci
Aslan FS, Barut B, Ozturk S, Eyigurbuz T, Akyuz E.   +4 more
europepmc   +1 more source